ecancermedicalscience

Research

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice

18 Jun 2012
M Origoni, P Cristoforoni, S Costa, L Mariani, P Scirpa, A Lorincz, M Sideri

The large amount of literature published over the last two decades on human papillomavirus (HPV)-DNA testing has definitely demonstrated the association between high-risk viral genotypes (hrHPV) and cervical cancer. Moreover, hrHPV-DNA testing has shown excellent performance in several clinical applications, from screening settings to the follow-up of treated patients, compared to conventional cytology or colposcopy options. On the other hand, when a huge number of reports are published on the same subject in a relatively short period of time, with many variations in settings, study designs and applications, the result is often confusion and decreased comprehension by readers. In daily office practice, several different situations (in symptomatic or asymptomatic women) can be positively managed by the correct use of hrHPV-DNA testing. Validated hrHPV-DNA testing and, specifically, the HC2® assay, due to its excellent sensitivity and negative predictive value together with optimal reproducibility, currently represent a powerful tool in the clinician’s hands to optimally manage several situations related to HPV infection and the potential development of cervical cancer.

Related Articles

Nazik Elmalaika Husain, Amira Burhan, Iman A I Ahmed, Sulma I Mohammed, Nazik Hammad
Priyal Chakravarti, Amita Maheshwari, Shweta Tahlan, Prithviraj Kadam, Sonali Bagal, Suvarna Gore, Nandkumar Panse, Kedar Deodhar, Pankaj Chaturvedi, Rajesh Dikshit, Atul Budukh
Tsion Afework, Birtukan Seid, Aderaw Anteneh, Wondimu Ayele, Seifu Hagos Gebreyesus, Bilal Shikur Endris
Lucrecia Aline Cabral Formigosa, Luciana Ferreira dos Santos, Joana Dulce Cabral Formigosa, Denise da Silva Pinto, Danielle Saraiva Tuma dos Reis, Marcos Valério Santos da Silva